Vaccine for existing HPV infection may thwart cervical cancer

Share this content:

A vaccine for women already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small study.

Most cervical cancers are caused by HPV infection. Unlike prophylactic vaccines that prevent the acquisition of HPV, VGX-3100 is a therapeutic vaccine designed to combat existing cervical cancer and control precancerous lesions, specifically those caused by HPV serotypes 16 and 18.

In a recent phase 1 study, 18 women previously treated for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3), a precursor to cervical cancer, received an intramuscular three-dose regimen of VGX-3100. The vaccine consists of highly engineered plasmid DNA encoding HPV 16 and HPV 18 E6/E7 antigens, working in a manner similar to that of gene therapy in that it inserts a piece of DNA that codes for a specific protein in the patient's cells. This produces another protein that directs the immune system to attack HPV-infected cells.

VGX-3100 delivery was accompanied by electroporation, a small electric pulse. As reported in Science Translational Medicine (2012;4[155]:155ra138), delivering the vaccine with electroporation induced a robust HPV-specific immune response in  previously infected individuals. Only minor side effects were seen at the range of doses tested.

These early results suggest that VGX-3100 could potentially spur cancer regression in individuals already infected with HPV, according to a news release from Science Translational Medicine.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs